DRG Epidemiology’s coverage of sickle cell disease (SCD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets in North America and Europe (the United States, France, Germany, Italy, Spain, and the United Kingdom). We report the diagnosed prevalence of SCD for each country, as well as annualized case counts projected to the national population.
The patient populations are forecast over a period of ten years.
DRG Epidemiology’s SCD forecast will answer the following questions:
Of all people diagnosed with SCD, how many in each of the pharmaceutical markets under study are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of SCD over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following SCD subpopulations:
Prevalence of Sickle Cell Disease per 1,000 People of All Ages in 2021 and 2031
Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Sickle Cell Disease Over the Next 10 Years
Analysis of the Prevalent Cases of Sickle Cell Disease in 2021 by Disease Subgroup
Analysis of the Diagnosed Prevalent Cases of Sickle Cell Disease in 2021 by Drug-Treated Status
Epidemiology Data
Methods
Diagnosed Prevalent Cases
Diagnosed Prevalent Cases by Disease Subgroup
Diagnosed Prevalent Cases by Treatment Status
Reference Materials
Literature Review
Studies Included in the Analysis of Sickle Cell Disease
Studies Excluded From the Analysis of Sickle Cell Disease
Risk/Protective Factors
Risk/Protective Factors for Sickle Cell Disease
Bibliography
Abbreviation Table
Glossary
Latashree Goswami
Latashree Goswami, M.P.H.,is an associate epidemiologist at Clarivate. She holds an M.P.H. from the Indian Institute of Public Health where she specialized in health economics, financing, and policy, and a B.D.S. from India’s ITS Dental College.
Mudasir Khan, M.P.H.
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry diseases. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.
